‹ Back
Tirzepatide
How it works
Tirzepatide drives two meal hormones at once: GIP for fat storage and nausea control, GLP-1 for appetite, stomach emptying and insulin, and together they reset insulin sensitivity in the liver and muscle.
Sources
Read the original sources
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. (Willard · 2020 · Abstract; full methods not assumed · checked 2026-10-13)
- A contemporary rationale for GIP receptor agonism in obesity, Samms 2025, Diabetes (Abstract · checked 2026-10-13)
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. (Coskun · 2018 · Abstract; full methods not assumed · checked 2026-10-13)
- Semaglutide lowers body weight in rodents via distributed neural pathways (2020 · Abstract; rodent mechanism · checked 2026-10-13)
- Dual GIP/GLP-1 receptor agonist tirzepatide, the new incretin summit, 2026, Effective Pharmacotherapy (Russia) (Summary · checked 2026-10-13)
- Tirzepatide: unimolecular polypharmacology for obesity, 2025, Endocrinology: News, Opinions, Training (Russia) (Summary · checked 2026-10-13)
- GLP-1 and dual GIP/GLP-1 receptor agonists: neuroendocrine mechanisms, Mysliwczyk 2026, Int J Mol Sci (Poland) (Abstract · checked 2026-10-13)